As of Q3'26 (2026-01-02), GEN reported R&D Expenses of USD 96M and SG&A Expenses of USD 377M. This marks a sequential decrease in R&D spending from the previous quarter's USD 100M, while SG&A Expenses saw a slight increase from USD 357M in Q2'26. Over the period from Q4'23 to Q3'26, SG&A Expenses have consistently represented the dominant portion of GEN's operating expenses, with a notable spike to USD 580M in Q2'24 before stabilizing in the USD 226M–377M range. R&D Expenses have remained comparatively stable, mostly fluctuating between USD 77M and USD 109M, with a sharp increase in Q1'26. Overall, the chart reveals that while R&D spending has shown moderate variability, SG&A Expenses have experienced more pronounced volatility, particularly in early fiscal 2024.